These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Virtual screening for alpha7 nicotinic acetylcholine receptor for treatment of Alzheimer's disease. Chen SG; Gu RX; Dai H; Wei DQ J Mol Graph Model; 2013 Feb; 39():98-107. PubMed ID: 23261879 [TBL] [Abstract][Full Text] [Related]
25. The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. Qi XL; Nordberg A; Xiu J; Guan ZZ Neurochem Int; 2007; 51(6-7):377-83. PubMed ID: 17493709 [TBL] [Abstract][Full Text] [Related]
26. In vivo Depiction of α7 Nicotinic Receptor Loss for Cognitive Decline in Alzheimer's Disease. Nakaizumi K; Ouchi Y; Terada T; Yoshikawa E; Kakimoto A; Isobe T; Bunai T; Yokokura M; Suzuki K; Magata Y J Alzheimers Dis; 2018; 61(4):1355-1365. PubMed ID: 29376856 [TBL] [Abstract][Full Text] [Related]
27. Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates Aβ accumulation through suppression of neuronal γ-secretase activity and promotion of microglial amyloid-β phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer's disease. Takata K; Amamiya T; Mizoguchi H; Kawanishi S; Kuroda E; Kitamura R; Ito A; Saito Y; Tawa M; Nagasawa T; Okamoto H; Sugino Y; Takegami S; Kitade T; Toda Y; Kem WR; Kitamura Y; Shimohama S; Ashihara E Neurobiol Aging; 2018 Feb; 62():197-209. PubMed ID: 29175709 [TBL] [Abstract][Full Text] [Related]
28. Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer's disease. Ma KG; Qian YH Neuropeptides; 2019 Feb; 73():96-106. PubMed ID: 30579679 [TBL] [Abstract][Full Text] [Related]
29. Time-dependent effect of oligomeric amyloid-β (1-42)-induced hippocampal neurodegeneration in rat model of Alzheimer's disease. Karthick C; Nithiyanandan S; Essa MM; Guillemin GJ; Jayachandran SK; Anusuyadevi M Neurol Res; 2019 Feb; 41(2):139-150. PubMed ID: 30453864 [TBL] [Abstract][Full Text] [Related]
30. Modeling subtype-selective agonists binding with alpha4beta2 and alpha7 nicotinic acetylcholine receptors: effects of local binding and long-range electrostatic interactions. Huang X; Zheng F; Chen X; Crooks PA; Dwoskin LP; Zhan CG J Med Chem; 2006 Dec; 49(26):7661-74. PubMed ID: 17181149 [TBL] [Abstract][Full Text] [Related]
31. Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease. Mousavi M; Hellström-Lindahl E; Guan ZZ; Shan KR; Ravid R; Nordberg A Neuroscience; 2003; 122(2):515-20. PubMed ID: 14614915 [TBL] [Abstract][Full Text] [Related]
32. Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach. Grupe M; Grunnet M; Bastlund JF; Jensen AA Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):187-200. PubMed ID: 25441336 [TBL] [Abstract][Full Text] [Related]
33. Effect of huprine X on β-amyloid, synaptophysin and α7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice. Hedberg MM; Clos MV; Ratia M; Gonzalez D; Lithner CU; Camps P; Muñoz-Torrero D; Badia A; Giménez-Llort L; Nordberg A Neurodegener Dis; 2010; 7(6):379-88. PubMed ID: 20689242 [TBL] [Abstract][Full Text] [Related]
34. SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist. Haydar SN; Ghiron C; Bettinetti L; Bothmann H; Comery TA; Dunlop J; La Rosa S; Micco I; Pollastrini M; Quinn J; Roncarati R; Scali C; Valacchi M; Varrone M; Zanaletti R Bioorg Med Chem; 2009 Jul; 17(14):5247-58. PubMed ID: 19515567 [TBL] [Abstract][Full Text] [Related]
35. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. Haydar SN; Dunlop J Curr Top Med Chem; 2010; 10(2):144-52. PubMed ID: 20166959 [TBL] [Abstract][Full Text] [Related]
36. Tropisetron and its targets in Alzheimer's disease. Hashimoto K Expert Opin Ther Targets; 2015 Jan; 19(1):1-5. PubMed ID: 25399811 [TBL] [Abstract][Full Text] [Related]
37. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Maelicke A; Schrattenholz A; Samochocki M; Radina M; Albuquerque EX Behav Brain Res; 2000 Aug; 113(1-2):199-206. PubMed ID: 10942046 [TBL] [Abstract][Full Text] [Related]
38. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517 [TBL] [Abstract][Full Text] [Related]
39. [Neuroprotective effects of alpha7 neuronal acetylcholine receptor and its roles in the pathogenesis of Alzheimer's disease]. Qi XL; Guan ZZ Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):51-5. PubMed ID: 18509986 [TBL] [Abstract][Full Text] [Related]